NASDAQ:AQST Aquestive Therapeutics - AQST Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.86 +0.02 (+2.38%) (As of 03/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.82▼$0.8650-Day Range$0.73▼$1.0052-Week Range$0.62▼$2.81Volume104,287 shsAverage Volume281,636 shsMarket Capitalization$46.58 millionP/E RatioN/ADividend YieldN/APrice Target$6.13 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Aquestive Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside865.1% Upside$8.30 Price TargetShort InterestHealthy3.38% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.78) to ($0.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.01 out of 5 starsMedical Sector836th out of 995 stocksPharmaceutical Preparations Industry405th out of 482 stocks 3.5 Analyst's Opinion Consensus RatingAquestive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.30, Aquestive Therapeutics has a forecasted upside of 865.1% from its current price of $0.86.Amount of Analyst CoverageAquestive Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.38% of the outstanding shares of Aquestive Therapeutics have been sold short.Short Interest Ratio / Days to CoverAquestive Therapeutics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Aquestive Therapeutics has recently decreased by 9.85%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAquestive Therapeutics does not currently pay a dividend.Dividend GrowthAquestive Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AQST. Previous Next 3.6 News and Social Media Coverage News SentimentAquestive Therapeutics has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aquestive Therapeutics this week, compared to 1 article on an average week.Search Interest18 people have searched for AQST on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Aquestive Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -79% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aquestive Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.75% of the stock of Aquestive Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 29.35% of the stock of Aquestive Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aquestive Therapeutics are expected to decrease in the coming year, from ($0.78) to ($0.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aquestive Therapeutics is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aquestive Therapeutics is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Aquestive Therapeutics (NASDAQ:AQST) StockAquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients' therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.Read More Receive AQST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AQST Stock News HeadlinesMarch 18, 2023 | americanbankingnews.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest UpdateMarch 10, 2023 | seekingalpha.comAquestive Therapeutics, Inc. (AQST) Q4 2022 Earnings Call TranscriptMarch 28, 2023 | Tradewins (Ad)Modern Day Options Trading For Beginners!These days it takes more than willpower to succeed on Wall Street and for new traders, even small mistakes can sink an account! With "Your Guide To Successful Options Trading" by expert Wendy Kirkland, you can avoid new trader pitfalls and learn to earn in this vicious market. March 10, 2023 | msn.comWedbush Upgrades Aquestive Therapeutics (AQST)March 9, 2023 | markets.businessinsider.comPositive Report for Aquestive Therapeutics (AQST) from WedbushMarch 9, 2023 | finance.yahoo.comQ4 2022 Aquestive Therapeutics Inc Earnings CallMarch 7, 2023 | msn.comAquestive Therapeutics GAAP EPS of -$0.23 in-line, revenue of $10.68M beats by $0.26MMarch 7, 2023 | finance.yahoo.comAquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 ObjectivesMarch 28, 2023 | Tradewins (Ad)Modern Day Options Trading For Beginners!These days it takes more than willpower to succeed on Wall Street and for new traders, even small mistakes can sink an account! With "Your Guide To Successful Options Trading" by expert Wendy Kirkland, you can avoid new trader pitfalls and learn to earn in this vicious market. March 1, 2023 | finance.yahoo.comAquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare ConferenceMarch 1, 2023 | finance.yahoo.comAssertio (ASRT) Reports Next Week: Wall Street Expects Earnings GrowthMarch 1, 2023 | finance.yahoo.comAquestive Therapeutics, Inc. (AQST)March 1, 2023 | finance.yahoo.comAquestive Therapeutics (AQST) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseFebruary 22, 2023 | finance.yahoo.comAquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ETFebruary 21, 2023 | finance.yahoo.comAquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual MeetingJanuary 31, 2023 | markets.businessinsider.comWedbush downgrades Aquestive Therapeutics (AQST) to a HoldJanuary 27, 2023 | finance.yahoo.comWhen Will Aquestive Therapeutics, Inc. (NASDAQ:AQST) Breakeven?January 26, 2023 | finanznachrichten.deDefence Therapeutics Inc.: Defence To Present at The 9th Annual Immuno-Oncology 360 Summit in New-York February 7-10, 2023January 6, 2023 | finance.yahoo.comAquestive Therapeutics Provides Business Update and Outlines Key 2023 ObjectivesDecember 23, 2022 | markets.businessinsider.comWedbush Reaffirms Their Buy Rating on Aquestive Therapeutics (AQST)December 22, 2022 | markets.businessinsider.comJMP Securities Keeps Their Buy Rating on Aquestive Therapeutics (AQST)December 22, 2022 | finance.yahoo.comAquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)November 29, 2022 | finance.yahoo.comAquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in EpilepsiaNovember 29, 2022 | seekingalpha.comAquestive Therapeutics: Going All-In On AQST-109November 15, 2022 | finance.yahoo.comAquestive Therapeutics to Participate in Two Upcoming Investor ConferencesNovember 9, 2022 | finance.yahoo.comAquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific MeetingNovember 2, 2022 | seekingalpha.comAquestive Therapeutics, Inc. (AQST) Q3 2022 Earnings Call TranscriptSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AQST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AQST Company Calendar Last Earnings3/08/2023Today3/28/2023Next Earnings (Estimated)5/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AQST CUSIPN/A CIK1398733 Webwww.aquestive.com Phone(908) 941-1900FaxN/AEmployees157Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.30 High Stock Price Forecast$17.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+612.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,410,000.00 Net Margins-114.11% Pretax Margin-147.69% Return on EquityN/A Return on Assets-99.12% Debt Debt-to-Equity RatioN/A Current Ratio1.04 Quick Ratio0.86 Sales & Book Value Annual Sales$47.68 million Price / Sales0.98 Cash FlowN/A Price / Cash FlowN/A Book Value($2.05) per share Price / Book-0.42Miscellaneous Outstanding Shares54,160,000Free Float48,876,000Market Cap$46.58 million OptionableNot Optionable Beta2.69 Key ExecutivesDaniel BarberPresident, Chief Executive Officer & DirectorCassie JungSenior Vice President-OperationsA. Ernest TothChief Financial Officer & Senior Vice PresidentA. Mark SchobelChief Technology & Innovation OfficerPeter BoydSVP-Human Resources & CommunicationsKey CompetitorsSynlogicNASDAQ:SYBXLifeVantageNASDAQ:LFVNSensei BiotherapeuticsNASDAQ:SNSENextCureNASDAQ:NXTCHookipa PharmaNASDAQ:HOOKView All CompetitorsInsiders & InstitutionsSchonfeld Strategic Advisors LLCBought 99,900 shares on 2/15/2023Ownership: 0.935%Millennium Management LLCSold 429,591 shares on 2/15/2023Ownership: 0.085%Renaissance Technologies LLCSold 438,063 shares on 2/13/2023Ownership: 0.854%Geode Capital Management LLCBought 21,676 shares on 2/13/2023Ownership: 0.716%Vahanian & Associates Financial Planning Inc.Sold 17,000 shares on 2/1/2023Ownership: 1.252%View All Insider TransactionsView All Institutional Transactions AQST Stock - Frequently Asked Questions Should I buy or sell Aquestive Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AQST shares. View AQST analyst ratings or view top-rated stocks. What is Aquestive Therapeutics' stock price forecast for 2023? 5 brokers have issued 12-month price targets for Aquestive Therapeutics' stock. Their AQST share price forecasts range from $4.00 to $17.00. On average, they anticipate the company's stock price to reach $8.30 in the next year. This suggests a possible upside of 865.1% from the stock's current price. View analysts price targets for AQST or view top-rated stocks among Wall Street analysts. How have AQST shares performed in 2023? Aquestive Therapeutics' stock was trading at $0.9021 at the beginning of 2023. Since then, AQST shares have decreased by 4.7% and is now trading at $0.86. View the best growth stocks for 2023 here. Are investors shorting Aquestive Therapeutics? Aquestive Therapeutics saw a drop in short interest in March. As of March 15th, there was short interest totaling 1,830,000 shares, a drop of 9.9% from the February 28th total of 2,030,000 shares. Based on an average daily trading volume, of 297,400 shares, the short-interest ratio is currently 6.2 days. View Aquestive Therapeutics' Short Interest. When is Aquestive Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023. View our AQST earnings forecast. How were Aquestive Therapeutics' earnings last quarter? Aquestive Therapeutics, Inc. (NASDAQ:AQST) issued its quarterly earnings results on Wednesday, March, 8th. The company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.02. The firm earned $10.68 million during the quarter, compared to analyst estimates of $9.93 million. During the same quarter in the prior year, the business posted ($0.38) EPS. What guidance has Aquestive Therapeutics issued on next quarter's earnings? Aquestive Therapeutics issued an update on its FY 2023 earnings guidance on Wednesday, March, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $37.00 million-$41.00 million, compared to the consensus revenue estimate of $37.83 million. What other stocks do shareholders of Aquestive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Organigram (OGI), Novan (NOVN), Outlook Therapeutics (OTLK) and KushCo (KSHB). When did Aquestive Therapeutics IPO? (AQST) raised $60 million in an IPO on Wednesday, July 25th 2018. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers. What is Aquestive Therapeutics' stock symbol? Aquestive Therapeutics trades on the NASDAQ under the ticker symbol "AQST." Who are Aquestive Therapeutics' major shareholders? Aquestive Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vahanian & Associates Financial Planning Inc. (1.25%), Schonfeld Strategic Advisors LLC (0.94%), Renaissance Technologies LLC (0.85%), Geode Capital Management LLC (0.72%), Millennium Management LLC (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alexander Mark Schobel, Daniel Barber, John T Maxwell, Keith J Kendall, Lori J Braender and Peter E Boyd. View institutional ownership trends. How do I buy shares of Aquestive Therapeutics? Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aquestive Therapeutics' stock price today? One share of AQST stock can currently be purchased for approximately $0.86. How much money does Aquestive Therapeutics make? Aquestive Therapeutics (NASDAQ:AQST) has a market capitalization of $46.58 million and generates $47.68 million in revenue each year. The company earns $-54,410,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. How many employees does Aquestive Therapeutics have? The company employs 157 workers across the globe. How can I contact Aquestive Therapeutics? Aquestive Therapeutics' mailing address is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. The official website for the company is www.aquestive.com. The company can be reached via phone at (908) 941-1900 or via email at investorrelations@aquestive.com. This page (NASDAQ:AQST) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.